BRAINS-BIOCEUTICAL-CORP.
16.6.2021 08:02:05 CEST | Business Wire | Press release
Brains Bioceutical Corp. (“Brains” or the “Company”) is pleased to announce the completion of a USD $31.9 million capital raise with DSM Venturing and existing Brains shareholders. DSM Venturing, who acted as lead investor in this round, is the corporate venture arm of Royal DSM (“DSM”), a global, purpose led science-based company active in health, nutrition and sustainable living. This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Del Morgan & Co. acted as Brains’ financial agent in respect to the capital raise.
“The completion of the capital raise marks an exciting milestone for the Brains’ team. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains' CEO & Chairman Rick Brar. “The growing demand for isolated CBD Active Pharmaceutical Ingredients (API’s) within the pharmaceutical and nutraceutical industry continues to expand. Our team has worked tirelessly to position Brains as the market leader within the CBD industry. Our suite of licences has allowed Brains to scale rapidly within the industry,” Brar continued.
Pieter Wolters, Managing Director DSM Venturing, commented: “The CBD market is fast-growing, powered by increasingly strong scientific evidence that demonstrate the potential of CBD API’s in a number of therapeutic areas. Also, consumers increasingly turn to CBD’s to address health issues. Brains unparalleled expertise and manufacturing capabilities in the CBD space combined with DSM’s unique scientific and marketing capabilities in the pharmaceutical sector make this the ideal partnership to help pharmaceutical players realizing the potential of CBD’s for early stage drug development.”
Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. It is also one of the rare few manufacturers in commercial production in Europe with EU-GMDP certification, producing CBD API for both human and veterinary use within a MHRA licensed facility. Brains’ CBD API—its primary offering to the market—contains 99.7% CBD and zero Tetrahydrocannabinol (THC).
Advancements made by Brains in the development of pure, natural CBD benefit the scientific and health care community on a global level. Brains phyto-cannabinoid pure CBD API has successfully been tested by the INRS Laboratory, a World Anti-Doping Agency (WADA) facility. These screening reports have confirmed that Brains’ CBD API is free of THC, pesticides and other banned substances listed by WADA. Brains is first of its kind in the industry to get such a confirmation from a WADA-accredited laboratory for the purity of its CBD and the absence of prohibitory substances. WADA has removed CBD from its banned substance list. All activities undertaken in the UK are in accordance with UK law and subject to routine, periodic inspection by UK authorities.
Brains has also launched its branded nutraceutical CBD “Brains Pure” products in top tier health and wellness retail and pharmacy chains in the UK. All Brains’ products—whether Brains-branded or white-labeled—including a partnership with a leading UK vitamin company, will bear the ‘Brains Inside®’ trademark, providing a stamp of quality assurance. Brains is also well positioned to navigate the strict Novel Foods requirements in the UK from the Food Standards Association (FSA) and in Europe by the European Food Safety Authority (EFSA) for CBD products. The Brains partnership with DSM Venturing will allow the company to take advantage of strategic partnerships that DSM has developed since their initial inception in 1902.
ABOUT BRAINS BIOCEUTICAL CORP.
Brains Bioceutical Corp. is a leader in EU-GMP-certified production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is one of the only natural plant-based cannabinoid active pharmaceutical ingredient (API) manufacturers in commercial production today and is involved in academic and clinical trials across the globe. Brains’ Senior Management Team is comprised of a rare hybrid of pharmaceutical and consumer goods executives-having held C-suite and other senior positions with companies such as GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal Navy. Brains' wholly owned subsidiary in the UK, BSPG Laboratories, is one of only a few companies that has the commercial capability and EU-GMDP certification to produce CBD API.
About DSM Venturing
DSM Venturing is the corporate venture arm of Royal DSM – a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM’s purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world’s biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.
More information can be found at www.dsm.com/venturing .
CAUTIONARY STATEMENT:
This news release contains forward looking statements or forward-looking information ("forward-looking statements") within the meaning of securities laws. Often, but not always, forward looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615006207/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ISC 2026: KAYTUS Unveils Gigawatt-Scale AI Infrastructure and Intelligent Management to Empower Europe’s AI Future25.6.2026 09:02:00 CEST | Press release
End-to-end, fully factory-prefabricated modular AI Factory deployment in just a few months, with full-stack intelligent management from GPU to rack, to the entire data center. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, unveiled two core solutions at ISC 2026, designed for next-generation AI data centers: a gigawatt-scale, fully prefabricated containerized liquid-cooled data center solution and KSManage Ultra, an intelligent operations management platform for AI Factories. Together, the solutions target the escalating efficiency, performance, scalability, and reliability requirements of AI-era infrastructure, enabling faster deployment, optimized thermal management, and unified operations across large-scale AI computing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625809392/en/ KAYTUS prefabricated containerized liquid cooled data center solution The KAYTUS gigawatt-scale
LR Health & Beauty SE Successfully Completes Financial Realignment – Strong Foundation for Growth and Long-Term Partnerships25.6.2026 09:00:00 CEST | Press release
Successful completion of the financial realignment enables full focus on growth and further strengthening operational excellence Planned investments in production and logistics will enhance efficiency, flexibility, and delivery capabilities Further international growth, including expansion into new markets, targeted LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has successfully completed its financial realignment, establishing the foundation for the company’s stable and forward-looking development. With the achievement of the final milestone, an intensive and demanding process has been successfully concluded. LR has fundamentally realigned its financing structure and significantly strengthened its capital base. An initial financing tranche of EUR 10 million was provided at the end of March, followed by a second tranche of the same amount in June. Jörg Körfer, CEO of LR Health & Beauty SE, comments: “The pas
YesWeHack Launches Agentic Pentest for AI Security Testing25.6.2026 09:00:00 CEST | Press release
New on-demand solution rapidly tests attack surfaces and centralises findings within YesWeHack’s offensive security platform YesWeHack, the offensive security and exposure management platform, announces Agentic Pentest, an on-demand solution using autonomous AI agents to test organisations' assets and deliver same-day findings. Shaped by YesWeHack’s extensive offensive security experience, Agentic Pentest helps organisations identify vulnerabilities, test their real-world exploitability and uncover attack paths across in-scope assets. The solution supports black box, grey box and white box testing of web applications, mobile apps, APIs and other internet-facing assets. YesWeHack, leader in offensive security in Europe and APAC, leverages the best available frontier models for offensive testing, including open-weight models. This flexible approach enables organisations to use models developed and/or hosted anywhere in the world, such as in EU or APAC. Agents operate within guardrails de
H2SITE Secures New Strategic Investment to Accelerate Industrial Deployment of Hydrogen Production and Separation Solutions25.6.2026 06:00:00 CEST | Press release
H2SITE, a leading industrial company in hydrogen production and separation solutions, has completed a second closing of its Series B round. The transaction brings in EIC Fund with a private investor who will support the company’s next phase of growth and increases H2SITE’s total funding raised in this round to more than €42 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624444396/en/ H2SITE These new partners, join BEV, Suma Capital, Hy24, Crane, Enagás Emprende, Calderion and CRPV who participated in the first closing, further validating the confidence of the European innovation ecosystem in H2SITE’s ability to industrialize and deploy key hydrogen solutions at commercial scale. Over the past years, H2SITE has successfully demonstrated the maturity and scalability of its technology, achieving more than 50,000 operating hours with its membrane reactors and separators, establishing advanced manufacturing capabilit
FPT Expands Strategic Collaboration with Microsoft to Advance AI Frontier Innovation Across Asia25.6.2026 04:00:00 CEST | Press release
FPT Corporation today announced an expanded strategic collaboration with Microsoft aimed at accelerating enterprise AI adoption and co‑innovation across Asia, with a strong focus on ASEAN, Japan, and South Korea. The collaboration brings together Microsoft’s global AI platforms with FPT’s large‑scale delivery and regional market capabilities to support organizations as they move from AI experimentation to real‑world, scalable impact, with measurable business outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624200416/en/ Representatives of FPT and Microsoft at the signing ceremony, formalizing an expanded strategic collaboration to advance AI Frontier innovation across Asia The collaboration aligns with FPT’s AI‑First strategy and Microsoft’s vision for human‑agent collaboration, with the goal of enabling enterprises to redesign how work is done across engineering, operations, and business functions. Positioning FP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom